Covid-19 (Temas de Saúde Pública)
Suécia suspende testagem de rotina para COVID-19 e retira as restrições devido a pandemia – “Somente profissionais da saúde e cuidadores de idosos, além dos mais vulneráveis, serão aptos a fazer teste de PCR gratuito se estiverem sintomáticos, enquanto o restante da população será orientado somente a permanecer em casa se apresentarem sintomas sugestivos de COVID-19.”
10 Fev, 2022 | 13:56hSweden ends COVID-19 testing as pandemic restrictions lifted – Associated Press
Conteúdos relacionados:
Covid: Europe set for ‘long period of tranquillity’ in pandemic, says WHO.
As Denmark scraps COVID restrictions, WHO urges caution.
Um estudo de base populacional no Catar mostrou que infecção prévia fornece proteção robusta contra reinfecção pelas variantes Alfa, Beta e Delta do SARS-CoV-2 (cerca de 90%). No entanto, a proteção contra reinfecção pela variante Ômicron foi menor (em torno de 60%).
10 Fev, 2022 | 13:54h
Comentário no Twitter
Using a national database in Qatar, investigators found that previous #SARSCoV2 infection provided protection against reinfection that ranged from 85% to 92% for alpha, beta, and delta strains and was approx 60% protective against omicron. #COVID19 https://t.co/SGODYCmkP3 pic.twitter.com/OkgjCbyZBj
— NEJM (@NEJM) February 9, 2022
Estudo randomizado | Análise final de eficácia e segurança da vacina de dose única da J&J.
10 Fev, 2022 | 13:53hFinal Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S – New England Journal of Medicine
Comentário no Twitter
A single injection of the Ad26.COV2.S Covid-19 vaccine showed 56.3% vaccine efficacy beginning 14 days after injection and 52.9% efficacy more than 28 days after injection against moderate to severe–critical #COVID19. #IDTwitter https://t.co/0VhaEUtmwq pic.twitter.com/04QqSyYwNI
— NEJM (@NEJM) February 9, 2022
Efetividade da vacinação heteróloga com CoronaVac e Pfizer no Brasil.
10 Fev, 2022 | 13:51hVaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil – Nature Medicine
Comentário no Twitter
An analysis of data from Brazil in @NatureMedicine shows that vaccine effectiveness against SARS-CoV-2 infection and severe COVID-19 outcomes declines after two doses of CoronaVac but increases after a booster dose of the Pfizer-BioNTech vaccine. https://t.co/UCgy6cJFIP pic.twitter.com/pXvkxZHXvv
— Nature Portfolio (@NaturePortfolio) February 9, 2022
OMS | Em 2 anos de pandemia de COVID, a maioria dos países ainda enfrenta importantes disrupções nos serviços de saúde.
10 Fev, 2022 | 13:16hRelatório original: Third round of the global pulse survey on continuity of essential health services during the COVID-19 pandemic – World Health Organization
Estudo de coorte | Saúde mental e física 3 meses depois da infecção por SARS-CoV-2 (“long COVID”) entre adolescentes na Inglaterra.
10 Fev, 2022 | 13:15hComentário: Long COVID and kids: more research is urgently needed – Nature
Conteúdos relacionados:
Editorial | Long covid in children and adolescents – “Risk appears low, but many questions remain”.
Review: Long COVID symptoms in children rarely persist beyond three months.
Comentário no Twitter (fio – clique para saber mais)
NEW RESEARCH: free! Two studies on adolescent #LongCovid. Both found high symptom burden in COVID positive and negative participants; very heterogenous symptom profile. Pandemic has had profound impact on all adolescents. https://t.co/YzU3ogXZrw pic.twitter.com/ina0DgPxBf
— The Lancet Child & Adolescent Health (@LancetChildAdol) February 8, 2022
[Preprint] Vigilância ativa de miocardite e pericardite decorrentes da vacinação contra COVID-19 com vacinas do tipo mRNA em pessoas de 12-39 anos na Itália.
10 Fev, 2022 | 13:13hConteúdos relacionados:
Myocarditis after BNT162b2 vaccination in Israeli adolescents.
[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.
Heart-inflammation risk from Pfizer COVID vaccine is very low.
Comentário no Twitter
The incidence of mRNA vaccine myocarditis or pericarditis in Italy in ~3 million vaccinees age 12-39. Excess cases per 100,000; orange is 2nd dose, blue 1st dose. https://t.co/xvdV4qSdHw
Pfizer:~1/100,000 age 12-39, all 2nd dose
Moderna,: >5/100,000, age 12-39, and some 1st dose pic.twitter.com/Y1jfGrU53v— Eric Topol (@EricTopol) February 9, 2022
Perspectiva | Rastreamento de infecções por COVID-19: hora da mudança.
10 Fev, 2022 | 13:09hTracking COVID-19 infections: time for change – Nature
Revisão sistemática | Terapia de observação por vídeo vs. terapia de observação direta em pacientes com tuberculose.
10 Fev, 2022 | 12:56hVideo-Observed Therapy Versus Directly Observed Therapy in Patients With Tuberculosis – American Journal of Preventive Medicine (link para o resumo – $ para o texto completo)
Conteúdo relacionado: RCT: Electronic directly observed therapy is noninferior to in-person observed therapy for ensuring adherence to tuberculosis treatment.
Comentário no Twitter
Our latest publication on @AmJPrevMed : Video-Observed Therapy Versus Directly Observed Therapy in Patients With Tuberculosis. Implementation of VOT improved medication adherence and bacteriological resolution compared with that of DOT in TB patients.https://t.co/xcWzrxLbHB? pic.twitter.com/4ldYJ2umd7
— Bang Truong (@bangphd_epi) December 13, 2021


